MERSANA THERAPEUTICS, INC.
MRSN US59045L1061
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -77% | -9% | -60% | -37% | -1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Huber Martin H. Jr. CEO |
7.31 USD |
2,012 Sold |
14,708 USD |
11/09/2025 | 12/09/2025 |
| Huber Martin H. Jr. CEO |
0.58 USD |
4,514 Sold |
2,618 USD |
15/01/2025 | 16/01/2025 |
| Lowinger Timothy B VP |
0.58 USD |
8,048 Sold |
4,668 USD |
15/01/2025 | 16/01/2025 |
| Protopapas Anna O |
0.58 USD |
8,637 Sold |
5,009 USD |
15/01/2025 | 16/01/2025 |
| Deschuytner Brian VP |
0.58 USD |
8,470 Sold |
4,913 USD |
15/01/2025 | 16/01/2025 |
| Carvajal Alejandra VP |
0.58 USD |
5,096 Sold |
2,956 USD |
15/01/2025 | 16/01/2025 |
| Bala Mohan VP |
0.58 USD |
5,939 Sold |
3,445 USD |
15/01/2025 | 16/01/2025 |
| Mandelia Ashish CCO |
0.58 USD |
3,554 Sold |
2,061 USD |
15/01/2025 | 16/01/2025 |
| Lowinger Timothy B VP |
0.63 USD |
1,794 Sold |
1,130 USD |
14/01/2025 | 15/01/2025 |
| Deschuytner Brian VP |
0.63 USD |
2,331 Sold |
1,469 USD |
14/01/2025 | 15/01/2025 |